2nd World Companion Diagnostics & Liquid Biopsy Summit APAC

Empowering Timely & Affordable Drug-Diagnostic Access Across APAC Through Harmonized Trial Management, Policy Shaping, & Testing Adoption. With rising demand for targeted therapies and testing access, the Asia-Pacific region is becoming a rising player in the co-development and commercialization of drug-diagnostic strategies. In under a year, Singapore has accelerated public-private partnerships to scale genomic testing, China has expanded national reimbursement for liquid biopsies, and Japan has refined its regulatory framework for companion diagnostic approvals. Returning for its second year, the World Liquid Biopsy & Companion Diagnostics Summit APAC will unite 100+ leaders across biopharma, diagnostics, regulation, and healthcare to drive the co-development and commercialization of affordable, scalable, and timely testing solutions.